Viatris Inc.는 북미, 유럽, 중국, 대만, 홍콩, 일본, 호주, 뉴질랜드, 아시아, 아프리카, 라틴 아메리카, 중동 지역에서 4개 사업 부문(Developed Markets, Greater China, JANZ, Emerging Markets)으로 운영되는 헬스케어 기업입니다. 이 회사는 처방 브랜드 의약품, 제네릭 의약품, 복합 제네릭 의약품, 바이오시밀러를 제공하며, 심혈관, 중추신경계 및 마취, 피부과, 당뇨병 및 대사, 안과, 위장병학, 면역학, 종양학, 호흡기 및 알레르기 등 다양한 치료 분야의 의약품을 취급합니다.
Viatris Inc.는 경구 고형제, 주사제, 복합 제형의 의약품을 소매 및 약국, 도매업체 및 유통업체, 지불자, 보험사 및 정부, 기관에 공급합니다. Lyrica, Lipitor, Celebrex, Viagra 등 다양한 브랜드로 제품을 유통하며, Mapi Pharma Ltd., Revance Therapeutics, Inc., Theravance Biopharma, Inc.와 협력 계약을 맺고 있습니다.
영어 원문 보기
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
